Mechanism
β2-adrenergic receptor (bronchodilator component) + glucocorticoid receptor (anti-inflammatory component)
Assets acting on this target.
- Class
- Not a single molecular entity — this is ClinicalTrials.gov's own comparator-arm intervention label from NCT00628758 (AstraZeneca's Symbicort Single Inhaler Therapy trial), describing the 'conventional best practice' control arm: a separate short/long-acting beta2-agonist bronchodilator (branded examples named in the registry record: Ventolin/salbutamol, Bricanyl/terbutaline, Serevent/salmeterol, Foradil/formoterol) taken alongside a separate inhaled corticosteroid (e.g. Seretide/fluticasone), as opposed to the trial's single-device Symbicort (budesonide/formoterol) arm. Not a discrete branded product with one mechanism.
- Pathway
- Bronchodilation (β2-receptor/cAMP signaling) plus separately-administered anti-inflammatory glucocorticoid receptor signaling — two established drug classes used as conventional combination care, not one fixed-dose combination
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.